43 results
20FR12B
EX-4.24
BLRX
Bioline Rx Ltd
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
).
Recalls. If any regulatory authority issues or requests a recall or takes a similar action in connection with the Product in a Party’s Territory … , or if a Party determines that an event, incident or circumstance has occurred that may result in the need for a recall or market withdrawal of Product
6-K
EX-99.3
BLRX
Bioline Rx Ltd
3 Mar 14
Current report (foreign)
12:00am
in the future, may require new regulatory clearances or approvals or may require us or our licensees, as applicable, to recall or cease marketing … , and, if necessitated by a problem with a marketed product, may result in the recall or suspension of marketing of the previously approved and marketed
6-K
EX-99.3
BLRX
Bioline Rx Ltd
5 Mar 15
Current report (foreign)
12:00am
that we or our licensees submit;
voluntary or mandatory recall;
fines;
refusal to permit the import or export of our products;
product seizure … , to recall or cease marketing these therapeutic candidates until clearances are obtained.
Modifications to our therapeutic candidates, after
424B2
BLRX
Bioline Rx Ltd
13 Jun 14
Prospectus for primary offering
12:00am
regulatory clearances or approvals or may require us or our licensees, as applicable, to recall or cease marketing these therapeutic candidates until … with a marketed product, may result in the recall or suspension of marketing of the previously approved and marketed product until clearances or approvals
F-3
BLRX
Bioline Rx Ltd
30 May 14
Shelf registration (foreign)
12:00am
or approvals or may require us or our licensees, as applicable, to recall or cease marketing these therapeutic candidates until clearances are obtained … , may result in the recall or suspension of marketing of the previously approved and marketed product until clearances or approvals of the modified
424B5
fviri u7zcwf
6 Feb 13
Prospectus supplement for primary offering
12:00am
424B5
wu8x2iugtue cou
4 Mar 14
Prospectus supplement for primary offering
12:00am
424B5
yvo hshast7xv
5 Mar 15
Prospectus supplement for primary offering
12:00am
424B5
7nol yk00
3 Mar 14
Prospectus supplement for primary offering
12:00am
424B5
6zvcmq0m55tjp7w nn3f
6 Mar 15
Prospectus supplement for primary offering
12:00am
20-F/A
EX-4.40
s30v66arvq 1tjs1y1
31 May 16
Annual report (foreign) (amended)
12:00am
6-K
EX-10.1
kp8bkdh
21 Sep 22
Current report (foreign)
8:00am
6-K
EX-10.1
x1onlx
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
6-K
EX-99
m5ml27 7yjh
28 May 20
Current report (foreign)
11:56am
6-K
EX-10.1
jwd39z6i7wgzuk98w d6
25 Sep 20
Current report (foreign)
4:33pm
6-K
EX-10.1
j9znjme
3 Sep 21
Current report (foreign)
4:30pm